Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Incyte Corporation — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.53 (market cap $2.14B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 11.5× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AMC | INCY | |
|---|---|---|
Market Cap | $2.14B | $24.54B |
Sector | Media | Health |
52-Week High | $3.15 | $129.93 |
52-Week Low | $0.95 | $81.61 |
Enterprise Value | $9.08B | $20.04B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.555, up 5.58% today, with a bullish technical signal and recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by strong box office performance and premium screen growth. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion as of 2024. Cash flow trends show improvement, with projected positive operating cash flow of $219 million in 2026.
Outlook is mixed; operational recovery and analyst consensus price target of $3.00 offer upside, but high debt and persistent losses pose significant risks. Investor sentiment is buoyed by record-breaking weekends and international expansion, yet volatility from meme-stock status and competitive pressures require caution.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
